Zila Appoints General Manager to Nutraceutical Division
April 05 2006 - 8:30AM
Business Wire
Zila, Inc.'s (Nasdaq: ZILA) wholly-owned subsidiary, Zila
Nutraceuticals, Inc., maker of Ester-C(R) and Ester-E(R), has
appointed industry veteran Bernie Landes as its Vice President and
General Manager. "Bernie's unique background and experience in the
nutraceutical market is ideal for leading the continued growth and
evolution of our Ester(TM) branded products as we position the
business to quickly achieve our larger strategic objectives for the
Company," said Douglas Burkett, Ph.D., Chairman, Chief Executive
Officer and President of Zila, Inc. "As we diversify and grow our
customer base both domestically and internationally, Bernie is the
perfect leader to launch Zila Nutraceuticals into this new phase of
growth." Mr. Landes recently served as President of Nutritional
Products Group providing services to the dietary supplement,
nutraceutical, personal care, environmental, functional and
traditional food industries. His other professional accomplishments
include serving as Chairman, President and CEO of Paracelsian,
Inc., General Manager for Alacer Corp., and Director of Marketing,
Strategic Planning, New Product Planning, Regulatory Affairs and
Nutrition Science for Health Valley Foods. Mr. Landes has a
Bachelor of Science in Business Administration and an MBA in
Marketing/Consumer Psychology, both from the University of
Delaware. "Ester-C is the industry's most successfully branded
vitamin C product. Extending the well-known Ester brand into new
delivery forms and categories which are almost limitless, is an
exciting opportunity," said Mr. Landes. "When I think of the market
potential of combining new product opportunities with entry into
some of the world's largest supplement markets, I envision
tremendous growth of marketshare for Zila." About Ester-C(R)
Ester-C is an advanced form of vitamin C that is pH neutral,
providing a form that is easily tolerated by the body. During the
patented process of producing Ester-C, the ascorbic acid undergoes
changes similar to those that occur in the body, which results in
vitamin C metabolites. It is the only vitamin C that contains these
metabolites, which help it work differently than regular vitamin C.
Ester-C has also been clinically proven to remain active in the
immune system for 24 hours. About Ester-E(R) Ester-E is an advanced
form of vitamin E containing d-alpha tocopheryl phosphates (or "TP"
for short). Until recently, scientists were unaware of this
important source of vitamin E in the body. Research suggests that
the human body may convert other forms of vitamin E into TP in
order to protect the vitamin's antioxidant strength until the body
is ready to use it. Scientists are now able to replicate this
natural form of vitamin E by joining a phosphate molecule to
natural vitamin E in a patented process, preserving vitamin E's
natural health benefits until the body is ready to use it.
Therefore, Ester-E is protected until it is needed, rather than
being used up prematurely. These statements have not been evaluated
by the Food and Drug Administration. This product is not intended
to diagnose, treat, cure or prevent any disease. Visit
www.Ester-E.com or www.Ester-C.com for more information about the
"Ester" line of premium products. About Zila, Inc. Zila, Inc.,
headquartered in Phoenix, is an innovator in preventative
healthcare technologies and products, focusing on enhanced body
defense and the detection of pre-disease states. Zila has three
business units: -- Zila Pharmaceuticals, marketer of products to
promote oral health and prevent oral disease, including ViziLite(R)
Plus oral examination kits and Peridex(R) prescription periodontal
rinse. -- Zila Biotechnology, a research, development and licensing
business specializing in pre-cancer/cancer detection through its
patented Zila(R) Tolonium Chloride and OraTest(R) technologies. --
Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and
Ester-E(R), branded, highly effective forms of Advanced Protection
vitamins C and E. For more information about Zila, visit
www.zila.com. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2005.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jul 2023 to Jul 2024